PPL 003Alternative Names: PPL-003
Latest Information Update: 14 Dec 2016
At a glance
- Originator Portage Biotech
- Developer EyGen; Portage Biotech
- Class Anti-inflammatories; Eye disorder therapies; Peptides; Recombinant fusion proteins
- Mechanism of Action NF-kappa B inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dry eyes; Neurological disorders; Uveitis